ClinicalTrials.gg
CompletedNCT01202084Updated Jun 18, 2015

A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients

A Phase 3 interventional study of Formoterol/Fluticasone and Foraseq® in Asthma, sponsored by Eurofarma Laboratorios S.A.. Completed at 1 site in Brazil. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2015-06-18.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 86 studies testing formoterol in Asthma — 2 open to participants now, 2 under way, 2 of them phase 3. formoterol · Asthma.

Enrollment
35th of 85
222 · median 100
Started
2012
with 2 others
Phase 3
48 of 86
2 open now
Registered
53rd of 86
by date
Lead sponsor
3 of 86
Eurofarma Laboratorios S.A.

Among the 86 studies testing formoterol in Asthma, this one is the 35th largest by enrollment of the 85 interventional ones that give a count, is one of 3 that started in 2012, is one of 48 in phase 3, and was the 53rd registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

2 of the 86 studies testing formoterol in Asthma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About formoterol

formoterol: first FDA approval 2001 (FORADIL), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing formoterol in Asthma, or all of them as a file.
02

Study summary

The primary objective will be to compare the impact of the study formulations on pulmonary function in persistent asthma carriers.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sign the ICF
  • Age ≥ 12 years
  • Persistent asthma diagnosis, as per the GINA classification (www.ginasthma.com),18 with symptoms for at least 6 months and clinically stable for at least 1 month, with the ACQ-745 test (see Appendix C) ≤ 3.0
  • Current use of inhaled (beclomethasone dipropionate dose of up to 1000 µg), associated or not with long-term β2-adrenergic agents and breakthrough medication (salbutamol or equivalent)
  • Initial of at least 40% of the predicted normal value
  • Serum cortisol assessment within normal values.

Exclusion criteria

Exclusion Criteria:

  • Use of oral or parenteral within the 3 months prior to study beginning
  • Requirement of admission due to asthma within the 3 months prior to study beginning
  • Presence of active smoking, defined as the use of cigarette, pipe, cigar or any form of smoking at any amount within the last 3 months
  • Presence of severe co-morbidities, such as cardiovascular, renal, liver, neurological, neoplastic, hematological, infectious, dermatological, neurological, psychiatric or chronic respiratory disease other than asthma
  • Recent (\< 6 months) or predicted participation during this study in other clinical studies involving drugs of any nature or in studies of any form of intervention for treating asthma
  • Intolerance or allergy to any of the components of the drugs assessed in the study
  • Pregnancy or lactation
  • Chronic use of β-blocker medications, per routine oral or intravenous route, or also as ophthalmic solutions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Formoterol/Fluticasone Eurofarma

    formoterol + fluticasone (12/250 mcg) twice a day per 12 weeks

    Drug: Formoterol/Fluticasone

  • Active comparator
    Foraseq®

    formoterol + budedonide (12/400 mcg) twice a day per 12 weeks

    Drug: Foraseq®

  • Active comparator
    Fluticasone

    fluticasone (500 mcg) twice a day per 12 weeks

    Drug: Fluticasone

Interventions

06

What researchers measure

Primary outcomes

  1. Forced expiratory volume in 1 second (FEV1) at final visit.

    Time frame: 12 weeks

Secondary outcomes

  1. Peak expiratory flow (PEF)

    Time frame: 12 weeks

07

Study locations

1 site
  • IMA Brasil - Instituto de Pesquisa Clínica e Medicina Avançada
    São Paulo, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2012, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2010
First posted
Sep 15, 2010
Start
Jan 2012
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Jun 18, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01202084
Responsible party
Sponsor
First posted
Sep 15, 2010
Start date
Jan 2012
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Jun 18, 2015

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Formoterol · Fluticasone

Start the discussion